Sharemaestro Newsreel

Biogen names Michael Parini as chief legal officer

Biogen Inc. has appointed Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of experience in the biopharmaceutical industry, having previously served as CEO of Spur Therapeutics and held leadership roles at Vertex Pharmaceuticals and …

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen

Novo Nordisk has received marketing authorization from the European Commission for its Wegovy pill and a higher-dose version of the Wegovy injectable in a single-dose pen. This approval means the once-daily oral option will be available across 27 EU countries.

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Novo Nordisk's oral Wegovy has received EU approval for weight management, causing NVO stock to jump 2.5%. This marks the fifth regulatory approval for the oral pill worldwide, and the company plans to launch it in more countries by late 2026. Retail investors have …

VivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth Guidance

VivoSim Labs announced it received a $5 million milestone payment from Eli Lilly, tied to the progression of an inflammatory bowel disease drug into Phase 2 studies. The company also projects over 500% revenue growth for Fiscal Year 2027, driven by increasing demand for …

Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

Biogen's anti-tau agent, diranersen, demonstrated significant slowing of cognitive decline across multiple endpoints in the Phase 2 CELIA trial for early Alzheimer's disease. The 60 mg dose showed the most consistent clinical benefit, including a 26% slowing on CDR-SB and reductions in CSF total …

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | Corporate

Septa Pharmaceuticals Inc. has announced the acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada, as of June 29, 2026. This acquisition strengthens Septa's specialty oncology pharmaceutical portfolio with an essential chemotherapy medication used primarily for brain tumors and Hodgkin's lymphoma. Septa is committed …

Once-weekly HIV combinations among Merck’s AIDS 2026 late-breakers

Merck announced it will present new data on daily, weekly, and monthly HIV treatment and prevention options from its pipeline at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Key presentations will feature late-stage clinical trial results for investigational once-weekly …

Johnson & Johnson MedTech sales grow 4.5% in Street-beating Q2, ups guidance

Johnson & Johnson (J&J) reported strong Q2 2026 results, surpassing Wall Street expectations with 4.5% growth in MedTech sales and overall sales of $25.3 billion. The company also raised its full-year revenue and adjusted EPS guidance, now expecting annual revenue to exceed $100 billion …

Johnson and Johnson Earnings Report | 2026 Q2 Infographic

Johnson & Johnson released its second-quarter 2026 earnings report, highlighting strong performance in its Innovative Medicine and MedTech businesses. The company reported a 6.6% increase in sales to $25.3 billion, with operational growth of 5.6%, and an adjusted EPS of $2.90. Joe Wolk, EVP …

Livforsakringsbolaget Skandia Omsesidigt Purchases 10,752 Shares of Amgen Inc. $AMGN

Livforsakringsbolaget Skandia Omsesidigt increased its stake in Amgen Inc. by 18.7% in the first quarter, now owning 68,130 shares valued at $23.95 million. This makes Amgen its 22nd biggest holding, constituting 1.0% of its portfolio. Other institutional investors also adjusted their positions in Amgen, …

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson exceeded second-quarter earnings and revenue expectations, prompting the company to raise its full-year guidance. This growth was primarily driven by the strong performance of its oncology portfolio, despite a decline in sales for its drug, Stelara. Despite the positive financial results, …

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson has raised its full-year guidance for sales and adjusted earnings per share after reporting higher sales in the latest quarter. The company now expects full-year sales of $100.8 billion to $101.4 billion and adjusted earnings per share between $11.60 to $11.75, …

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson surpassed Wall Street expectations for its second-quarter sales and profit, primarily driven by strong performance in its pharmaceutical unit, particularly from Darzalex and Tremfya. The company also raised its full-year sales and profit outlook, despite a slight dip in its medical …

Form S-1 Biogen Inc For: 15 July By Investing.com

This article from Investing.com announces the filing of Form S-1 by Biogen Inc. on July 15. The content primarily consists of navigation links, market data, and unrelated news headlines, providing minimal specific details about the Biogen filing itself.

Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s Data - Has The Bull Case Changed?

Biogen's stock is down 6.7% following the launch of at-home LEQEMBI IQLIK for early Alzheimer's and new positive Phase 2 data for diranersen. The at-home option for LEQEMBI aims to improve access and uptake, which is crucial for Biogen's investment narrative amidst revenue pressure …

LGT Fund Management Co Ltd. Grows Stake in Johnson & Johnson $JNJ

LGT Fund Management Co Ltd. significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 770.7% in the first quarter, now owning 112,310 shares valued at $27.45 million. Other institutional investors have also adjusted their holdings, while Johnson & Johnson's stock is trading down …

Carnegie Investment Counsel Sells 34,449 Shares of Johnson & Johnson $JNJ

Carnegie Investment Counsel has reduced its stake in Johnson & Johnson ($JNJ) by 21.5% in the first quarter, selling 34,449 shares. Despite this, institutional investors still hold a significant 69.55% of the company's stock, and investor sentiment remains largely positive ahead of Q2 earnings, …

AMG National Trust Bank Has $4.59 Million Stock Position in Amgen Inc. $AMGN

AMG National Trust Bank significantly increased its stake in Amgen Inc. to $4.59 million, holding 13,034 shares by the first quarter's end. This move follows Amgen's strong first-quarter financial performance, which exceeded revenue and EPS expectations. Despite positive analyst ratings and an upbeat outlook …

Johnson & Johnson $JNJ Shares Sold by Arbejdsmarkedets Tillaegspension

Arbejdsmarkedets Tillaegspension reduced its stake in Johnson & Johnson ($JNJ) by 7.4% in the first quarter, selling 8,626 shares, though the company remains a significant holding for the fund. Despite this, institutional investors broadly hold a large percentage of JNJ's shares, and analysts generally …

Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday

Morgan Stanley, Johnson & Johnson, Pentair PLC, ASML Holding NV, and Progressive Corp. are among the stocks to watch heading into Wednesday's trading. Morgan Stanley, Johnson & Johnson, and Progressive Corp. are set to release their quarterly earnings reports. Pentair PLC announced a CFO …

Should Gilead’s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences reported a Q3 revenue beat of US$6.96 billion, exceeding analysts' expectations by 1.5%, but concurrently issued a softer full-year earnings-per-share outlook. This outcome suggests that while sales are strong, the company faces challenges in translating this growth into sustained profitability, raising questions …

Johnson & Johnson (JNJ) approaches earnings after 2.3% weekly setback

The healthcare heavyweight reports July 15, with longer-period gains and lighter turnover making the setup more balanced than the weekly drop alone suggests.

Johnson & Johnson (JNJ) brings a 13.0% four-week climb into July 15 earnings

The Healthcare heavyweight has momentum in weekly context, while lighter volume keeps the pre-results setup from looking fully confirmed.

AbbVie’s range-top push rests on June’s 87.5M-share breakout, not fresh July volume

ABBV closed within 0.2% of its 52-week high after a 14.9% four-week run, but the latest advance came on 0.9x volume and leaves valuation distance stretched.

Novo Nordisk A/S (NVO) extends 30.0% 12-week advance as activity picks up

The healthcare heavyweight is recovering on weekly data, but the setup still lacks clean trend confirmation.

AbbVie Inc (ABBV) director acquisition adds insider angle to a strong tape

The disclosure gives investors a governance marker as the drugmaker trades with heavier turnover and firm relative performance.

Eli Lilly’s 10% week puts it 0.6% from a yearly high while Fair Value stretch widens

LLY finished at $1,208 after a strong week on above-average participation, but the stock now sits 51.1% above Sharemaestro Fair Value as Healthcare breadth remains selective.

Novartis’s 18.3M-share rebound keeps its 63-week Trend Signal intact, but pressure is still negative

Novartis outpaced its drugmaker group for the week on heavy volume, yet the broader confirmation picture is mixed as Market Dynamics remains below zero.

Novo Nordisk A/S (NVO) draws heavier tape as 12-week rebound reaches 30.0%

The healthcare heavyweight is recovering in weekly context, but Relative Strength remains negative and the trend signal has not reactivated.

Merck’s 13% week outruns drugmaker breadth and lands within 0.1% of its yearly high

MRK closed at $128.70 after a high-range advance on 64.4M shares, with the weekly Trend Signal still active but Market Dynamics short of a fresh buy confirmation.

Johnson & Johnson’s 54.9M-share high tests the limit of an unconfirmed advance

JNJ jumped 11.5% to finish just 0.2% below its 52-week high, but negative activity pressure and a 52% Fair Value premium keep the weekly setup from being one-sided.

AbbVie Inc (ABBV) gets a 17.0% weekly reset on heavy turnover

The healthcare heavyweight’s latest weekly move sharpened a broader four-week advance, though the trend signal has not yet turned active.

Scilex Holding Company (SCLX) Dips 5.2% as Stock Tests Key Support Levels - Technical Analysis

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

Johnson & Johnson (JNJ) insider filing adds an executive acquisition

The update gives investors a fresh ownership datapoint as the drugmaker is viewed through weekly market data rather than live intraday action.